Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

SciClone Pharma (6600 HK): Privatisation At IPO Price

SciClone Pharmaceuticals (6600 HK): 19th June Shareholder Vote

SciClone Pharma (6600 HK): Inexpensive Ahead Of New Therapies Rolling Out

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

SciClone Pharmaceuticals IPO Valuation: Not Pleasing

Quiddity Advisors

Event-Driven

<ul>
<li>A little over a year ago, shareholders approved <strong><a href="https://www.smartkarma.com/entities/sciclone-pharmaceuticals-holdings-limited" target="_blank" data-smartkarma-citation="entities:17351:1" rel="noopener">Sciclone Pharmaceuticals (6600 HK)</a></strong>'s buyback, which lifted GL Capital's holding to 31.63% from 28.09%, enabling creep provisions.</li>
<li>After the share price gained 14% yesterday, SciClone was suspended pursuant to the Code on Takeovers and Mergers before trading commenced this morning. Mmm.</li>
<li>GL Capital, together with CDH Investments, Ascendent Capital Partner, Ocean Falcon Limited, and Boying Investments Limited, took SciClone private in 2017. Time for another privatisation?</li>
</ul>


A little over a year ago, shareholders approved Sciclone Pharmaceuticals (6600 HK)'s buyback, which lifted GL Capital's holding to 31.63% from 28.09%, enabling creep provisions.
After the share price gained 14% yesterday, SciClone was suspended pursuant to the Code on Takeovers and Mergers before trading commenced this morning. Mmm.
GL Capital, together with CDH Investments, Ascendent Capital Partner, Ocean Falcon Limited, and Boying Investments Limited, took SciClone private in 2017. Time for another privatisation?


Hollysys Automation Technologies (HOLI US)

SciClone Pharma (6600 HK): GL Capital Consortium Reload?